← Oncology Approval Tracker

FDA DECISION ·

Zusduri

mitomycin intravesical solution · UroGen Pharma

FDA approvalNew formulationNon-muscle-invasive bladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer.

LAMPGEN ANALYSIS

Why it matters

A bladder-instilled gel-forming mitomycin option addresses recurrent intermediate-risk low-grade disease.

What research teams should watch

Build capacity for weekly catheter instillations and harmonize follow-up cystoscopy and cytology across sites.

PRIMARY RECORDS

Sources